Pharmaceuticals

Eylea Market Growth Projection: Expected to Surpass $14.79 Billion by 2030 at 7.3% CAGR

March 2, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the eylea market from 2026–2035 with trusted insights from The Business Research Company

How much is the Eylea Market valued at in 2026, and what valuation is forecast for 2030?

The eylea market size has demonstrated substantial growth over recent years. This market is anticipated to expand from $10.51 billion in 2025 to $11.15 billion by 2026, exhibiting a compound annual growth rate (CAGR) of 6.2%. Historically, this expansion has been driven by factors such as the increasing prevalence of age-related macular degeneration, an aging global population, the strong clinical effectiveness of anti-VEGF drugs, a rise in ophthalmology specialty centers, and comprehensive reimbursement support for retinal therapies.

The eylea market is anticipated to experience substantial growth over the next few years, with projections indicating it will reach $14.79 billion in 2030, achieving a compound annual growth rate (CAGR) of 7.3%. This expansion during the forecast period is attributable to an increasing diabetic population, the broadening of applications to additional retinal disorders, advancements in long-acting formulation development, improved drug delivery formats, and enhanced access in emerging markets. Major trends foreseen for this period include the development of extended-interval anti-VEGF therapies, a shift towards prefilled syringe adoption, growing application in diabetic retinopathy treatment, an increase in hospital-based intravitreal procedures, and a heightened focus on real-world evidence and outcomes.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=9155&type=smp

What Drivers Are Influencing The Growth Of The Eylea Market?

The increasing prevalence of ocular diseases is set to propel the Eylea market. These conditions refer to eye ailments that interfere with the eye’s proper functioning, negatively affecting vision and clarity. They often present no symptoms until they have reached an advanced stage. Eylea provides treatment for various ocular diseases, including wet age-related macular degeneration (AMD) and glaucoma, both of which damage the retina or macula, thus impacting vision. Eylea functions by blocking the protein responsible for the development of new, weaker blood vessels and by reducing the swelling in the retina caused by blockages in the blood vessels. For instance, in 2024, according to the BrightFocus Foundation, a U.S.-based nonprofit organization focused on macular degeneration and glaucoma research, approximately 80 million people globally are living with glaucoma, and this number is projected to rise to 111 million by 2040. Consequently, the escalating incidence of ocular diseases is a key factor driving the Eylea market.

How Is The Eylea Market Organized Into Various Segments?

The eylea market covered in this report is segmented –

1) By Product: Prefilled Syringe Package, Vial Package

2) By Disorder: Wet Age-Related Macular Degeneration (AMD), Diabetic Retinopathy, Other Disorders

3) By Application: Hospitals, Retail Pharmacy, Other Applications

Subsegments:

1) By Prefilled Syringe Package: Single-Dose Prefilled Syringes, Multi-Dose Prefilled Syringes

2) By Vial Package: Single-Dose Vials, Multi-Dose Vials

What Industry Trends Are Transforming The Eylea Market?

Leading companies in the eylea market are concentrating on developing biologic treatments, such as aflibercept biosimilars, to gain a competitive edge. An aflibercept biosimilar is a biologically similar version of the reference drug aflibercept, engineered to have no clinically significant differences and providing a cost-effective alternative for the management of specific eye conditions. For example, in September 2023, Biocon Biologics Ltd., an India-based biopharmaceutical firm, secured marketing authorization from the European Commission (EC) for YESAFILI, an aflibercept biosimilar, within the European Union (EU). This approval followed a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) in July. YESAFILI is an ophthalmology product designed for treating various eye conditions, and its authorization confirms its comparability in terms of quality, safety, and efficacy to the reference product Eylea (aflibercept).

Who Are The Major Companies Operating In The Eylea Market?

Major companies operating in the eylea market are Regeneron Pharmaceuticals Inc., Bayer AG, Novartis AG, Roche Holding AG, Pfizer Inc., Amgen Inc., Sanofi S.A., AbbVie Inc., Alcon Inc., Genentech Inc., Johnson & Johnson, Samsung Bioepis Co. Ltd., Boehringer Ingelheim GmbH, Eisai Co. Ltd., Daiichi Sankyo Company Limited, Aerie Pharmaceuticals Inc., Otsuka Pharmaceutical Co. Ltd., Santen Pharmaceutical Co. Ltd., Allergan plc, BioMarin Pharmaceutical Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/eylea-global-market-report

Which Region Is Anticipated To See The Fastest Growth In The Eylea Market?

North America was the largest region in the eylea market in 2025. Asia-Pacific is expected to be the fastest-growing region in the eylea market during the forecast period. The regions covered in the eylea market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Eylea Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=9155&type=smp

Browse Through More Reports Similar to the Global Eylea Market 2026, By The Business Research Company

Eylea Market Report 2026

https://www.thebusinessresearchcompany.com/report/eylea-global-market-report

Xylene Market Report 2026

https://www.thebusinessresearchcompany.com/report/xylene-global-market-report

Vanadium Market Report 2026

https://www.thebusinessresearchcompany.com/report/vanadium-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795